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The bone marrow is a favored site for a number of cancers, including the hemato-
logical malignancy multiple myeloma, and metastasis of breast and prostate cancer. 
This specialized microenvironment is highly supportive, not only for tumor growth and 
survival but also for the development of an associated destructive cancer-induced bone 
disease. The interactions between tumor cells, osteoclasts and osteoblasts are well doc-
umented. By contrast, despite occupying a significant proportion of the bone marrow, 
the importance of bone marrow adipose tissue is only just emerging. The ability of bone 
marrow adipocytes to regulate skeletal biology and hematopoiesis, combined with their 
metabolic activity, endocrine functions, and proximity to tumor cells means that they are 
ideally placed to impact both tumor growth and bone disease. This review discusses 
the recent advances in our understanding of how marrow adipose tissue contributes to 
bone metastasis and cancer-induced bone disease.
Keywords: cancer-induced bone disease, marrow adipose tissue, multiple myeloma, prostate cancer, bone 
metastasis
inTRODUCTiOn
For the majority of cancers, surgical removal of an isolated primary tumor can be curative. However, 
once tumor cells establish residence in other organs patient mortality is markedly increased. Once 
detached from the primary site, a single or cluster of tumor cells can circulate the body and establish 
secondary lesions in distant sites. Metastasis is a highly inefficient process with <0.1% of disseminat-
ing cells surviving to form secondary lesions (1). This implies that healthy tissues display a level of 
hostility toward invading tumor cells, and so in order to survive and repopulate new sites these cells 
need to have adapted to seek out more permissive environments to occupy. Interestingly, it has long 
been recognized that each type of tumor has a distinct pattern of dissemination. In 1889, Stephen 
Paget published a paper proposing that disseminating cancer cells or “seeds” would only colonize 
secondary sites or “soils” that were compatible with their growth (2). This theory was challenged in 
the 1920s by James Ewing who proposed that the colonization of secondary sites could be explained 
purely by circulatory patterns between the primary and secondary sites (3). In fact, these theories are 
not mutually exclusive, as there is evidence to support both (1). Systemic breast cancer commonly 
metastasizes to the bones, lungs, liver, and brain most of which do not have a direct circulatory link 
to breast tissue. Advanced prostate cancer also selectively metastasizes to bone. By contrast, patients 
suffering from colon cancer often develop initial metastases in the liver (4). Therefore, mechanical 
factors that govern the amount of cancer cells delivered to an organ, and compatibility factors such 
as whether the organ preferentially supports the growth of a specific tumor cell type, contribute 
to cancer spread (5). Once a cancer cell has successfully seeded itself, it is then dependent on the 
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molecular interactions between it and the environment of the 
new organ. The more permissive the environment, the more likely 
the tumor cell is able to take advantage and thrive.
THe BOne MiCROenviROnMenT
Bone or bone marrow is a major target organ for metastasis, 
providing a fertile “soil” for circulating tumor cells to settle and 
repopulate. It is the preferential site of a number of solid tumor 
metastases including breast and prostate, of which 70–80% of 
advanced cases have bone involvement (6, 7). It is also the site 
of the fatal hematological malignancy, multiple myeloma. The 
bone consists of a number of different cell types, including 
endothelial cells and nerve cells, cells of hematopoietic origin, 
such as hematopoietic stem cells, osteoclasts macrophages, and 
lymphocytes, as well as cells from mesenchymal origin, such as 
chondrocytes, osteoblasts, and adipocytes. Together these cells 
provide a supportive niche via cellular cross-talk that maintains 
healthy bone. It is thought that cancer cells are able to hijack this 
support network to transform what was initially a beneficial niche 
into a deadly one. Considerable research efforts have been made, 
attempting to understand the complexity of the bone microen-
vironment and defining the exact contribution of each cell type 
in tumor growth and metastasis. Mundy and colleagues greatly 
broadened our understanding of this by introducing the concept 
of the “vicious-cycle” involving bi-directional interactions of 
tumor cells and bone cells, resulting in osteolysis and in turn, 
tumor growth. Breast cancer cells produce parathyroid hormone-
related peptide (PTHrP) that activates osteoblasts to produce 
receptor activator of nuclear factor kappa-B ligand (RANKL) 
and downregulate osteoprotegerin (OPG). This in turn activates 
osteoclast precursors, leading to osteolysis. The breakdown of 
the bone matrix releases bone-derived growth factors, such as 
transforming growth factor-β and insulin-like growth factor 1, 
and raises extracellular calcium concentrations. The growth fac-
tors bind to receptors on the cell surface of the tumor cells and 
activate SMAD and MAPK signaling, extracellular calcium binds 
and activates calcium pumps leading to tumor cell proliferation 
and the production of PTHrP, thereby causing a vicious cycle of 
events that result in osteolytic lesions and the progression of can-
cer metastasis (8–10). This theory explained how bone cells and 
cancer cells could have a reciprocal relationship. However, it does 
not take into consideration the contribution of the other resident 
cells of the bone marrow, such as the cells of the immune system, 
which have also been shown to play an important part in cancer 
progression (11, 12). In recent years, the contribution of bone 
marrow adipocytes (BMAs) has also come into question. Cancer 
primarily occurs in older people whose bone marrow is highly 
populated by adipocytes. In early childhood, the bone marrow 
exists in a predominantly red/hematopoietic osteogenic state (13) 
and there are few if any detectable adipocytes, however, by the age 
of 25, ~70% of bone marrow volume is filled with adipose tissue 
(14). This constitutes around 2 kg of marrow adipose tissue in a 
healthy adult that represents over 10% of total adipose mass (15). 
Longitudinal analysis of patients from birth to 90 years have dem-
onstrated that even after this initial exponential accumulation, 
there continues to be a gradual increase in adipocyte number 
throughout adult life (16). These cells were previously thought to 
be inert space filling bystanders (17). However, recently that way 
of thinking has changed and it is becoming clear that adipocytes 
have a definite and significant contribution to the bone micro-
environment and, thus, the establishment of metastatic disease.
BOne MARROw ADiPOCYTeS
Over the last century, our knowledge and understanding of the 
role of BMAs has been slowly growing. At the beginning of the 
nineteenth century, it was determined that the skeleton is filled 
with areas consisting of yellow or red marrow that are distributed 
in a defined pattern (18). A number of decades later, it was shown 
using elegant ultrastructural studies that BMAs develop from a 
unique progenitor when compared to white adipocytes (19), and 
that there are two distinct populations of BMAs that respond 
differently to hematopoietic demands (20). This phenomenon 
was also shown by Scheller and colleagues that marrow adipose 
tissue may exist in two isoforms, “constitutive” that forms early 
on in development in sites such as the distal tibia, and “regulated” 
that tends to develop with aging and is located interspersed with 
hematopoietic cells at sites such as the proximal femur and lum-
bar vertebrae (21). The fact that marrow adipose tissue develops 
in a conserved, spatial, and temporal manner implies that it is the 
product of a defined developmental event; suggesting that it has 
a distinct physiological function. Its phenotype resembles both 
brown and white adipose tissue; and unlike white adipose tissue, 
it is not strictly associated with BMI or body fat. It is known to 
be increased in patients suffering from anorexia nervosa, despite 
their lean appearance (22). It is also elevated in young mice in 
response to calorie restriction (23). The main functions of bone 
marrow adipose tissue are to serve as an energy reservoir and 
secrete fatty acids, cytokines, and adipokines. BMAs store energy 
in the form of lipid and release triglycerides and fatty acids in 
response to energy demands. They are smaller than their visceral 
counterparts; however, due to enhanced triacylglycerol synthesis 
the net effect of fatty acid uptake is similar (24). BMAs are both 
an endocrine target and have endocrine-like functions: respond-
ing to growth hormones insulin and thyroid hormone, as well as 
releasing cytokines such as IL-6, IL-1β, and TNF-α (25). They also 
secrete adipokines, among them leptin and adiponectin, which 
regulate calorie uptake and insulin sensitivity, respectively. They 
can potentially influence neighboring cells via autocrine, parac-
rine, and endocrine signaling (26) making them an influential 
component of the bone microenvironment. BMAs arise from 
multipotent mesenchymal progenitors; these cells have the capac-
ity to differentiate into several cell types, including myocytes, 
chondrocytes, osteoblasts, and adipocytes (27, 28). It is thought 
that downstream of these multipotent progenitors, bipotent 
osteoblast–adipocytes progenitors form an intermediate in the 
process of cell commitment to these two cell lineages (29). These 
bipotent cells are stimulated to commit to either cell lineage by 
the presence of adipogenic vs. osteogenic factors within the bone 
microenvironment that activate their respective transcriptional 
programs (30, 31). This creates an inverse reciprocal relationship 
between osteoblastogenesis and adipogenesis, with factors that 
promote one of these processes usually inhibiting the other. Many 
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have likened it to a see-saw, when one process goes up the other 
often comes down and vice versa (32). It has also been suggested 
that mature osteoblasts and adipocytes are able to dedifferenti-
ate and transdifferentiate from one phenotype to the other (33). 
Work by Martin and colleagues also demonstrated that BMAs 
are able to influence their environment by secreting extracellular 
vesicles containing adipogenic mRNA transcripts. These could 
be taken up and expressed by neighboring osteoblasts, thereby 
weakening their lineage commitment (34, 35). The net result 
of this close relationship is that if the balance tips in flavor of 
adipogenesis, osteoblast number may be reduced, resulting in 
a decrease in bone, so compromising bone strength. BMAs are 
not only negative regulators of bone formation but also serve to 
inhibit hematopoiesis. The number of BMAs has been shown 
to be inversely correlated with the hematopoietic activity of the 
marrow (36). The evidence to support the notion that BMAs play 
a metabolic role in the bone is quite clear; however, the influence 
they have in the context of cancer development and progression 
is still poorly understood.
wHiTe ADiPOSe TiSSUe; A GROwinG 
COnTRiBUTOR TO CAnCeR RiSK AnD 
PROGReSSiOn
White adipose tissue (WAT) was the first adipose tissue type to be 
heavily studied in relation to cancer development and progression. 
In 2002, the International Agency for Research on Cancer (IARC) 
conducted an evaluation on whether there was a link between 
weight and cancer. They concluded that the risk of developing 
some cancers was increased with weight gain (37). Since then, 
there have been numerous studies investigating the association 
between increased adiposity and cancer, suggesting that obesity 
is associated with an increased risk of developing a number of 
different tumor types, such as colon, breast, and endometrial 
cancer (38–40). As adipose tissue expands, adipocytes enlarge to 
store excess energy intake. This causes an increased production 
of a number of different adipokines and inflammatory cytokines 
coupled with a decrease in adiponectin, as well as a diminished 
ability of adipocytes to store surplus-free fatty acids. These 
changes are associated with dysfunctional WAT that often leads to 
insulin resistance. In turn, the suppression of lipolysis by insulin 
is inhibited in insulin resistance, resulting in an increased release 
of free fatty acids, thereby setting up a vicious cycle of events (40). 
Lipids are crucial for malignant tumors as they are necessary for 
the synthesis of membrane constituents; they are also an effective 
bioenergetic source when metabolic demands are high. In 2011, 
Nieman et al. demonstrated that adipocytes–ovarian cancer cell 
co-culture led to the direct transfer of lipids from adipocytes to 
ovarian cancer cells and promoted in  vitro and in  vivo tumor 
growth. Furthermore, co-culture induced lipolysis in adipocytes 
and β-oxidation in cancer cells, suggesting that the adipocytes act 
as an energy source for the cancer cells (41). Adipocytes were also 
shown to promote the direct migration of prostate cancer cells 
(42), as well as promote colon cancer proliferation (43). Similar 
findings have been reported in breast cancer studies, which 
demonstrate that adipocytes located close to invasive cancer cells 
are essential for breast tumor development and progression (44). 
Moreover, adipocytes promote drug resistance in HER2 positive 
breast cancer cells, suggesting that they bestow a level of protec-
tion upon tumor cells (45). Dysfunctional WAT appears to have 
a tumor-promoting role; it may be that cancer cells that have 
been in close proximity to adipocytes are primed to settle in an 
adipocyte-rich secondary site, making the bone a hospitable and 
permissive environment (Figure 1).
BOne MARROw ADiPOCYTeS; FUeLinG 
CAnCeR PROGReSSiOn
Once WAT had been identified as a driver of cancer progression, 
the contribution of adipocytes from different anatomical sites 
came into question. There are now a number of publications 
highlighting the importance of BMAs as a lipid source that can 
be utilized by cancer cells to promote proliferation, migration, 
and invasion (46, 47). A key factor implicated in Nieman’s 2011 
study was fatty acid binding protein 4 (FABP4); a lipid chaperone 
that mediates lipid trafficking and transfer of free fatty acids, 
predominantly expressed in adipocytes, macrophages, and 
endothelial cells (41). Herroon et al. took these findings further 
using a mouse model of diet-induced marrow adiposity and 
demonstrated that FABP4 along with interleukin 1β and its target 
gene, oxidative stress protein, heme oxygenase 1 (HMOX-1) was 
also upregulated in prostate cancer cells that were in direct contact 
with BMAs (46). Taken together, these studies support the fact 
that cancer cells are able to utilize marrow adipocyte-supplied 
lipids to thrive in skeletal sites. They also open up a number of 
questions as to whether BMAs are utilized in the same manner as 
WAT or whether they offer different environmental advantages to 
some cancer types over others.
ADiPOKineS/CYTOKineS
Similarly to WAT, BMAs are not only an effective source of energy 
they also secrete a plethora of bioactive substances, such as IL-1β, 
IL-6, leptin, adiponectin, VCAM-1, TNF-α, and VEGF (25). As 
well as being important in the context of maintaining healthy 
bone, these secreted cytokines, adipokines, and growth factors 
can also influence cancer cell behavior and survival. Increased 
IL-1β secretion coupled with increased leptin expression was 
shown to recruit breast cancer cells to colonize in bone marrow 
adipose tissue (47). IL-6, TNF-α, CXCL12, and leptin were shown 
to promote cell proliferation and migration, as well as inhibit 
apoptosis and activate autophagy to promote chemotherapy 
resistance in multiple myeloma (25, 48–51). In prostate cancer, 
the chemokines, CXCL1 and CXCL2, have been implicated in the 
progression of associated bone disease by activating osteoclas-
togenesis and thus promoting tumor cell survival (52). Similarly, 
in melanoma increased IL-6 triggered an increase in osteoclas-
togenesis resulting in tumor cell proliferation (53). BMAs clearly 
influence cancer cell establishment and progression in bone. 
However, they also play a known tumor-suppressive role. BMAs 
are the largest source of circulating adiponectin in the body, far 
more than white adipose tissue (54). Adiponectin has been shown 
FiGURe 1 | An overview of the potential contribution of both white adipose tissue (wAT) and bone marrow adipocytes (BMAs) to the vicious cycle of 
bone metastases. Dysfunctional WAT releases an increased level of a number of adipokines and pro-inflammatory cytokines that can support tumor growth. In 
turn, cancer cells may cause delipidation of adipocytes to fuel their growth and the acquisition of an aggressive metastatic phenotype. They can then metastasize to 
the adipocyte-rich environment of the bone where they may continue to utilize BMAs generated from mesenchymal stem cells (MSC) that reside in the bone, as a 
source of fuel. Cancer cells residing in the bone produce various cytokines and growth factors that primarily target osteoblasts, causing them to increase their 
production of receptor activator of nuclear factor kappa-B ligand (RANKL). RANKL in turn targets the RANK receptor expressed by osteoclast precursors and leads 
to differentiated and activated osteoclasts. The osteoclasts degrade the bone releasing numerous factors. Many of these factors act positively upon the cancer cells 
resulting in a vicious cycle.
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to exert anti-tumor effects (55, 56), and its levels are inversely 
correlated with a number of different cancers, such as myeloma, 
breast, prostate, colon, and endometrial cancer (57, 58), and are 
associated with poor prognosis (59). Interestingly, unlike other 
adipokines, such as leptin, circulating adiponectin levels are also 
decreased in obesity, which appears to be somewhat paradoxical 
as the numbers of adipocytes are increased. Reduced circulat-
ing adiponectin in obesity is likely derived from dysfunctional 
adipocytes that have decreased adiponectin expression and secre-
tion, which may be the result of mitochondrial dysfunction or 
increased inflammation, hypoxia or endoplasmic reticulum stress 
due to the challenge of a high fat diet (60). These findings trigger 
the question as to what causes the downregulation of adiponectin 
expression in cancer? Is it a consequence of cancer progression 
or a cause? Do cancer cells secrete factors that directly regulate 
adiponectin levels? Are adiponectin levels compromised before 
cancer development by conditions, such as obesity, that allow for 
a more permissive environment? More research needs to be done 
to address these questions and to validate whether adiponectin 
signaling may be a future therapeutic target.
TARGeTinG BOne MARROw 
ADiPOCYTeS
Given the mounting evidence to support the negative role of 
BMAs in cancer progression, as is further discussed in the con-
text of myeloma by Falyank et al. (61), targeting these cells either 
alone or in combination with conventional therapeutics may be 
a promising approach. Due to the ability of cancer cells to induce 
lipidation of BMAs to support their energy expenditure, drugs are 
now being developed that target essential molecules of fatty acid 
synthesis and uptake. Chemical or RNAi mediated inhibition of 
fatty acid synthase, acetyl-CoA-carboxylase or ATP-citrate lyase 
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was shown to attenuate cancer cell proliferation and cell survival 
in both in vitro and in vivo models (62–64). Another approach is 
to regulate the balance between osteogenesis and adipogenesis 
by targeting PPARγ or glucocorticoid receptor signaling, thereby 
preventing an increase in marrow adiposity (65). The modulation 
of adipokines although still in its infancy has also shown encour-
aging effects. Leptin receptor antagonists were shown to inhibit 
tumor cell growth in a model of triple-negative breast cancer (66). 
Enhancement of circulating adiponectin levels by the apolipopro-
tein mimetic L-4F caused cancer cell death in a mouse model of 
multiple myeloma (55). Furthermore, a peptide-based adiponec-
tin receptor agonist ADP 355 was shown to suppress the growth 
of orthotopic human breast cancer xenografts by ~31% (67). As 
we begin to gain more knowledge of the exact contribution of 
BMAs to disease progression, targeting strategies will inevitably 
become clearer. First, though we need to understand whether 
BMAs are simply power stations that fuel an inevitable process? 
If they were removed from the equation, would the cancer cells 
still home to the bone and thrive? Or are BMAs an integral part 
of the metastatic process, fertilizing the soil so circulating cancer 
cells can settle and progress. Interestingly, marrow adipose tis-
sue unlike white adipose tissue increases in times of starvation. 
Calorie restriction has been show to not only increase marrow 
adiposity but also extend lifespan in a number of diverse species, 
such as rodents and primates (68, 69), and is associated with a 
decrease in cancer risk (70). These findings suggest that BMAs 
have a protective function that is contradictory to the evidence 
to suggest that they promote cancer progression. However, one 
question that remains unresolved is whether the BMAs generated 
by weight gain and sedentary behavior are the same as those 
generated by calorie restriction? It may be that BMAs gener-
ated by calorie restriction are more metabolically aware and, 
therefore, less responsive to cancer cell manipulation. However 
more research needs to be done to explore these possibilities. 
Targeting BMAs as part of a combination therapy may prove 
to be a valuable tool; however, first there needs to be a greater 
understanding of the balance between the tumor-promoting and 
tumor-suppressive effects of these cells.
COnCLUSiOn
As the field of marrow adiposity advances and we come to fully 
appreciate and understand the influence BMAs have on disease 
progression, drugs that target these cells may start to come into 
their own and open up new therapeutic avenues. These advances 
will hopefully move us one step closer to successfully treating 
lethal metastatic cancer.
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